Protara Therapeutics (TARA) Other Non-Current Assets (2014 - 2026)
Protara Therapeutics (TARA) posted quarterly Other Non-Current Assets of $76000.0 for Q1 2026, down 89.8% year-over-year from $745000.0 in Q1 2025, and down 97.42% quarter-over-quarter from $2.9 million in Q4 2025.
Protara Therapeutics (TARA) Other Non-Current Assets (2014 - 2026) Analysis & Trends
Protara Therapeutics (TARA) has reported Other Non-Current Assets for 13 consecutive years, with $76000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 89.8% year-over-year to $76000.0; the TTM figure through Mar 2026 stood at $76000.0 (down 89.8% YoY), while the FY2025 annual figure was $2.9 million, up 295.97% from the prior year.
- Other Non-Current Assets declined to $76000.0 in Q1 2026 per TARA's latest filing, from $2.9 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $2.9 million in Q4 2025 and bottomed at $29000.0 in Q2 2025.
- Historically, Other Non-Current Assets has averaged $789764.7 across 5 years, with a median of $745000.0 in 2022.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets jumped 1474.0% — and 2025, when it sank 96.11%.
- Protara Therapeutics' Other Non-Current Assets stood at $644000.0 in 2022, then increased by 15.68% to $745000.0 in 2023, then changed by 0.0% to $745000.0 in 2024, then jumped by 295.97% to $2.9 million in 2025, then sank by 97.42% to $76000.0 in 2026.
- Business Quant data shows TARA's Other Non-Current Assets at $76000.0 in Q1 2026, $2.9 million in Q4 2025, and $745000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Protara Therapeutics | 234.56 Mn | 234.56 Mn | - | 5.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.92 Mn |
| Mar 31, 2026 | 76,000.00 |
| Dec 31, 2025 | 2.95 Mn |
| Sep 30, 2025 | 745,000.00 |
| Jun 30, 2025 | 29,000.00 |
| Mar 31, 2025 | 745,000.00 |
| Dec 31, 2024 | 745,000.00 |
| Sep 30, 2024 | 745,000.00 |
| Jun 30, 2024 | 745,000.00 |
| Mar 31, 2024 | 745,000.00 |
| Dec 31, 2023 | 745,000.00 |
| Sep 30, 2023 | 745,000.00 |
| Jun 30, 2023 | 745,000.00 |
| Mar 31, 2023 | 745,000.00 |
| Dec 31, 2022 | 644,000.00 |
| Sep 30, 2022 | 745,000.00 |
| Jun 30, 2022 | 745,000.00 |
| Mar 31, 2022 | 787,000.00 |
| Dec 31, 2021 | 865,000.00 |
| Sep 30, 2021 | 745,000.00 |